AU670125B2 - Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists - Google Patents

Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists

Info

Publication number
AU670125B2
AU670125B2 AU49209/93A AU4920993A AU670125B2 AU 670125 B2 AU670125 B2 AU 670125B2 AU 49209/93 A AU49209/93 A AU 49209/93A AU 4920993 A AU4920993 A AU 4920993A AU 670125 B2 AU670125 B2 AU 670125B2
Authority
AU
Australia
Prior art keywords
method
tumor necrosis
necrosis factor
factor antagonists
treating tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU49209/93A
Other versions
AU4920993A (en
Inventor
Cindy A. Jacobs
Craig A. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US94623692A priority Critical
Priority to US946236 priority
Application filed by Immunex Corp filed Critical Immunex Corp
Priority to PCT/US1993/008666 priority patent/WO1994006476A1/en
Publication of AU4920993A publication Critical patent/AU4920993A/en
Application granted granted Critical
Publication of AU670125B2 publication Critical patent/AU670125B2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU670125(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Anticipated expiration legal-status Critical
Application status is Expired legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
AU49209/93A 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists Expired AU670125B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US94623692A true 1992-09-15 1992-09-15
US946236 1992-09-15
PCT/US1993/008666 WO1994006476A1 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists

Publications (2)

Publication Number Publication Date
AU4920993A AU4920993A (en) 1994-04-12
AU670125B2 true AU670125B2 (en) 1996-07-04

Family

ID=25484181

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49209/93A Expired AU670125B2 (en) 1992-09-15 1993-09-14 Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists

Country Status (8)

Country Link
EP (1) EP0620739A4 (en)
JP (1) JPH07504203A (en)
KR (1) KR100232688B1 (en)
AU (1) AU670125B2 (en)
CA (1) CA2123593C (en)
NO (1) NO941780A (en)
NZ (1) NZ256293A (en)
WO (1) WO1994006476A1 (en)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT289350T (en) * 1989-04-21 2005-03-15 Amgen Inc Tnf-receptor, tnf binding proteins and encoding it dnas
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
ES2197149T3 (en) * 1992-03-30 2004-01-01 Immunex Corporation Fusion proteins comprising two receptors for tumor necrosis factor.
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
AU3111995A (en) * 1994-07-22 1996-02-22 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
AU4658596A (en) * 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
AU715260B2 (en) * 1995-07-14 2000-01-20 Laboratoires Serono Sa TNF receptor and steroid hormone in a combined therapy
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU725408B2 (en) * 1996-05-08 2000-10-12 F. Hoffmann-La Roche Ag Treatment of asthma with TNFR-Ig
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
AU5696198A (en) * 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
SI0942740T1 (en) * 1996-12-06 2003-12-31 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
CA2290021A1 (en) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy
AU8492598A (en) * 1997-07-17 1999-02-10 Regents Of The University Of Michigan, The Methods and compositions for tumor reduction
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
EP1097165A4 (en) * 1998-07-13 2001-09-12 Parkash S Gill Novel inhibitors of angiogenesis and tumor growth
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1206275B1 (en) * 1998-11-05 2007-09-05 Omeros Corporation Irrigation solution and method for inhibition of pain and inflammation
TR200504220T2 (en) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Active lymphotoxin-beta receptor immunoglogulin şimeaktif lymphotoxin-beta receptor immunoglogulin yöntem.ırıl to a method for high level expression and purification of high-level expression of the chimeric protein and saflaştrik protein.
IL127851D0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
EP1165116A1 (en) * 1999-04-02 2002-01-02 Immunex Corporation Use of soluble tumor necrosis factor receptor for treating heart failure
WO2000073481A1 (en) * 1999-05-28 2000-12-07 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
EP1939300A1 (en) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
AT399025T (en) * 1999-07-21 2008-07-15 Omeros Corp Irrigation solutions and methods for inhibition of pain, inflammation inhibition and inhibition of cartilage degradation
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
MXPA02001264A (en) 1999-08-04 2002-07-22 Amgen Inc Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY.
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
JP2003533986A (en) 2000-05-04 2003-11-18 エイブイアイ バイオファーマ, インコーポレイテッド Splice regions antisense compositions and methods
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
AU2003267999B2 (en) 2002-07-19 2010-03-11 Abbvie Biotechnology Ltd Treatment of TNFalpha related disorders
US20060140933A1 (en) * 2002-08-16 2006-06-29 Wyeth And Imperial College Innovations Limited Compositions and methods for treating rage-associated disorders
WO2004024915A1 (en) * 2002-09-13 2004-03-25 The University Of Queensland Gene expression system based on codon translation efficiency
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
DE602004013557D1 (en) * 2003-02-28 2008-06-19 Ares Trading Sa LIQUID FORMULATIONS OF TUMORNEKROSEFRAKTOR binding protein TBP-1
US20080241884A1 (en) * 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
TWI556829B (en) 2004-04-09 2016-11-11 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating tnfα-related disorders
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
WO2006053301A2 (en) * 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
EP2089521A1 (en) * 2006-02-08 2009-08-19 Ercole Biotech, Inc. Soluble tnf receptors and their use in treatment of disease
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7919264B2 (en) 2005-11-01 2011-04-05 Abbott Biotechnology Ltd. Methods and compositions for determining the efficacy of a treatment for ankylosing spondylitis using biomarkers
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
US7972599B2 (en) 2006-03-20 2011-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US7863426B2 (en) 2006-04-05 2011-01-04 Abbott Biotechnology Ltd. Antibody purification
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
EP2666479A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of juvenile rheumatoid arthritis
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd Uses and compositions for treatment of psoriatic arthritis
WO2008005315A2 (en) 2006-06-30 2008-01-10 Abbott Biotechnology Ltd. Automatic injection device
JP2010501622A (en) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Purification of Fc- fusion protein
EA017733B1 (en) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. PROCESS FOR THE PURIFICATION OF Fc-FUSION PROTEINS
JP2010501623A (en) 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Purification of Fc-containing protein
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2073833A2 (en) 2006-10-20 2009-07-01 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNF-alpha INHIBITORS IN AUTOIMMUNE DISORDERS
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
BRPI0813452A2 (en) 2007-06-14 2017-05-23 Galactica Pharmaceuticals Inc RAGE fusion proteins.
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
AU2009280913A1 (en) * 2008-08-12 2010-02-18 Avesthagen Limited An expression vector and a method thereof
BRPI0923806A2 (en) 2008-12-30 2015-07-14 Centocor Ortho Biotech Inc Serum markers for predicting the clinical response to anti-TNF antibodies in patients with ankylosing spondylitis
US8636704B2 (en) 2009-04-29 2014-01-28 Abbvie Biotechnology Ltd Automatic injection device
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
AU2010325943A1 (en) 2009-12-02 2012-06-21 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of Fc fusion proteins.
AU2010330907A1 (en) 2009-12-16 2012-06-14 Bosch, Phillip Methods of treating interstitial cystitis
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
CA2789168A1 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. Methods and compositions for predicting responsiveness to treatment with tnf-.alpha. inhibitor
RU2573042C2 (en) 2010-04-21 2016-01-20 Эббви Байотекнолоджи Лтд. Worn device for automatic injection for controlled supply of therapeutic agents
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
ES2685607T3 (en) 2010-06-03 2018-10-10 Abbvie Biotechnology Ltd Uses and compositions for treating hidradenitis suppurativa (HS)
FR2962335B1 (en) 2010-07-12 2013-01-18 Cll Pharma Using the nonapeptide pat in the treatment and prevention of neurodegenerative diseases
WO2012019099A2 (en) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Follistatin-like-protein-1 as a biomarker for inflammatory disorders
RU2016139357A (en) 2011-01-24 2018-12-13 Эббви Байотекнолоджи Лтд. Automatic injection devices having over molded gripping surface
AU2012231178B2 (en) 2011-03-18 2015-11-05 Abbvie Inc. Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof
US9956353B2 (en) 2011-03-29 2018-05-01 Abbvie Inc. Shroud deployment in automatic injection devices
CN107096098A (en) 2011-04-21 2017-08-29 艾伯维公司 Wearable automatic injection device
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc Compositions and methods for increasing serum half-life
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
KR101525919B1 (en) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 Bispecific antibody based on TNFR2 for preventing and traeating autoimmune disease
AU2015241373A1 (en) 2014-03-31 2016-10-06 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
BR112017013269A2 (en) 2014-12-22 2018-02-27 Ares Trading Sa ? Liquid pharmaceutical composition?
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
CA3019003A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3257866A1 (en) 2016-06-17 2017-12-20 Academisch Medisch Centrum Modified anti-tnf antibody and use thereof in the treatment of ibd

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5138493A (en) * 1992-09-22 1994-04-12 Cell Therapeutics, Inc. Novel epoxide-containing compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2065346C (en) * 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
WO1992013095A1 (en) * 1991-01-18 1992-08-06 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5138493A (en) * 1992-09-22 1994-04-12 Cell Therapeutics, Inc. Novel epoxide-containing compounds

Also Published As

Publication number Publication date
NZ256293A (en) 1997-06-24
KR100232688B1 (en) 1999-12-01
AU4920993A (en) 1994-04-12
NO941780A (en) 1994-07-15
EP0620739A4 (en) 1997-01-15
EP0620739A1 (en) 1994-10-26
WO1994006476A1 (en) 1994-03-31
NO941780D0 (en) 1994-05-11
CA2123593A1 (en) 1994-03-31
JPH07504203A (en) 1995-05-11
CA2123593C (en) 2000-03-14

Similar Documents

Publication Publication Date Title
AU682818C (en) Use of substituted adenine derivatives for treating multiple sclerosis
AU635002B2 (en) Methods and compositions for treatment of cancer using oligonucleotides
AU678788B2 (en) Method of preparing coating materials
AU661640B2 (en) Method and apparatus for radiation therapy
AU654120B2 (en) Solid tumor treatment method and composition
AU670413B2 (en) Compositions and methods for treating wounds
AU692429B2 (en) Magnetotherapy apparatus
AU3724993A (en) Use of substituted adenine derivatives for treating multiple sclerosis
PL178088B1 (en) Method of treating liguids
SG55131A1 (en) Tumor necrosis factor (TNF) inhabitor and method for obtaining the same
GR3025953T3 (en) Substituted amidino compounds, their manufacture and methods of treatment.
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
GR3031681T3 (en) Method of treating pulmonary inflammation.
AU4032989A (en) Method and compositions for the treatment and prevention of septic shock
AU3763893A (en) Methods for producing members of specific binding pairs
AU2259292A (en) Treatment of neuropsychiatric disorders by nerve stimulation
AU5323194A (en) Compositions for treatment of inflamed tissues
GR3033327T3 (en) Methods for treating tumor necrosis factor mediated diseases.
AU3965093A (en) CDMA frequency allocation
HU9403369D0 (en) Treatment of incontinence
PL299002A1 (en) Method of obtaining arylo-piperazinylo-heterocyclic compounds
AU3078092A (en) Treatment of waste
AU3548795A (en) Benzopyranopyrazolyl derivatives for the treatment of inflammation
AU2662092A (en) Method and apparatus for wide area antitachycardia pacing
PL173066B1 (en) Method of obtaining pyrimidinic compounds